AR009128A1 - Un compuesto de 8-aril-1,7-naftiridina, composiciones farmaceuticas que lo comprenden, utilizacion de dicho compuesto para la fabricacion de medicamentos,procedimiento para la preparacion de tal compuesto y productos intermedios utilizados en dicha preparacion - Google Patents

Un compuesto de 8-aril-1,7-naftiridina, composiciones farmaceuticas que lo comprenden, utilizacion de dicho compuesto para la fabricacion de medicamentos,procedimiento para la preparacion de tal compuesto y productos intermedios utilizados en dicha preparacion

Info

Publication number
AR009128A1
AR009128A1 ARP970104916A ARP970104916A AR009128A1 AR 009128 A1 AR009128 A1 AR 009128A1 AR P970104916 A ARP970104916 A AR P970104916A AR P970104916 A ARP970104916 A AR P970104916A AR 009128 A1 AR009128 A1 AR 009128A1
Authority
AR
Argentina
Prior art keywords
compound
preparation
aryl
pharmaceutical compositions
amino
Prior art date
Application number
ARP970104916A
Other languages
English (en)
Original Assignee
Garcia Cattebeke Cybele Carina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garcia Cattebeke Cybele Carina filed Critical Garcia Cattebeke Cybele Carina
Publication of AR009128A1 publication Critical patent/AR009128A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Las novedosas 8-aril-1,7-naftiridinas, en forma libre o de sal, constituyen inhibidores de PDE IV y, de esta manera, son utiles como productosfarmacéuticos, por ejemplo, para la terapia contra el asma. Los compuestos que se prefieren incluyen losco mpuestos de las formulas (I) y (II) donde R1, esfenilo, bencilo, 3-nitrofenilo, 3-clorofenilo, 3-cianofenilo, 3-(tetrazoilil) fenilo, benzofurazanilo o benzotiofurazanilo; R2 es hidroxi, amino,trifluorometanosulfonilo, alilo alquilo, alquenilo,alq uinilo, alcoxi, arilo, aralquilo, ariloxi, arilamino, diarilamino, alcamino, dialcamino, alcarilo,arilamido, o alcamido; R3 es H y R4 es nitro, halo, ciano, o tetrazolilo; y R5 y R6, en conjunto, forman un enlace adicional; o R3, R4, R5 y R6,en c onjunto,son =N-O-N= o =N-S-N=; y R7 es hidroxi, amino, alquilamino C1-4 o alcoxi C1-4, preferentemente hidroxi o amino. Se presentan las composiciones farmacéuticasque comprenden los compuestos, los procedimientos para la preparacion de loscompu estos y los intermediarios novedosos para su uso en los procedimientos.
ARP970104916A 1996-10-28 1997-10-24 Un compuesto de 8-aril-1,7-naftiridina, composiciones farmaceuticas que lo comprenden, utilizacion de dicho compuesto para la fabricacion de medicamentos,procedimiento para la preparacion de tal compuesto y productos intermedios utilizados en dicha preparacion AR009128A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622386.2A GB9622386D0 (en) 1996-10-28 1996-10-28 Organic compounds

Publications (1)

Publication Number Publication Date
AR009128A1 true AR009128A1 (es) 2000-03-08

Family

ID=10802050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104916A AR009128A1 (es) 1996-10-28 1997-10-24 Un compuesto de 8-aril-1,7-naftiridina, composiciones farmaceuticas que lo comprenden, utilizacion de dicho compuesto para la fabricacion de medicamentos,procedimiento para la preparacion de tal compuesto y productos intermedios utilizados en dicha preparacion

Country Status (31)

Country Link
US (1) US6136821A (es)
EP (1) EP0934320B1 (es)
JP (1) JP4451496B2 (es)
KR (1) KR100524329B1 (es)
CN (1) CN1103773C (es)
AR (1) AR009128A1 (es)
AT (1) ATE236155T1 (es)
AU (1) AU724471B2 (es)
BR (1) BR9713280B1 (es)
CA (1) CA2269946C (es)
CO (1) CO4910164A1 (es)
CZ (1) CZ146699A3 (es)
DE (1) DE69720493T2 (es)
DK (1) DK0934320T3 (es)
ES (1) ES2196377T3 (es)
GB (1) GB9622386D0 (es)
HU (1) HUP9904204A3 (es)
ID (1) ID18623A (es)
IL (2) IL129502A0 (es)
MY (1) MY132642A (es)
NO (1) NO312677B1 (es)
NZ (1) NZ335363A (es)
PE (1) PE10899A1 (es)
PL (1) PL189280B1 (es)
PT (1) PT934320E (es)
SI (1) SI0934320T1 (es)
SK (1) SK283562B6 (es)
TR (1) TR199900920T2 (es)
TW (1) TW399052B (es)
WO (1) WO1998018796A1 (es)
ZA (1) ZA979593B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020079T2 (de) 1999-01-15 2006-01-19 Altana Pharma Ag Phenanthridin-N-oxide mit PDE-IV-hemmender Wirkung
ES2241571T3 (es) * 1999-01-15 2005-11-01 Altana Pharma Ag N-oxidos de fenantrinida con actividad inhividora de pde-iv.
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
CN1489588A (zh) 2001-01-31 2004-04-14 �Ʒ� 用作pde4同功酶抑制剂的噻唑基,噁唑基,吡咯基,和咪唑基羧酸酰胺衍生物
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EE200300360A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
ES2248231T3 (es) 2001-01-31 2006-03-16 Pfizer Products Inc. Derivados de eteres utiles como inhibidores de las isozimas pde4.
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
IL161317A0 (en) * 2001-10-16 2004-09-27 Memory Pharm Corp 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
US7507707B2 (en) 2001-12-14 2009-03-24 Laboratoires Serono Sa Methods of inducing ovulation using a non-polypeptide camp level modulator
CA2506297A1 (en) 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
SG169900A1 (en) * 2003-04-16 2011-04-29 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
EP1631568A1 (en) * 2003-04-18 2006-03-08 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2006073413A1 (en) * 2004-02-20 2006-07-13 The Board Of Trustees Of The University Of Illinois Blood pressure reduction in salt-sensitive
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US20050282818A1 (en) * 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20070293678A1 (en) * 2004-09-14 2007-12-20 Xinglong Jiang Process For The Preparation Of 6, 8-Subs Tituted '1, 7 Naphthpyridin Derivatives By Reacting The 8-Halo-'1, 7 Naphthpyrid In-Derivate With An Organic Boronic Acid Derivatives And Intermadiates Of This Process
EP1799673A1 (en) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
EP1802615A1 (en) * 2004-10-20 2007-07-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
JP2006241111A (ja) * 2005-03-04 2006-09-14 Univ Nihon 新規ベンゾフロキサン及びその合成法
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
ES2340531T3 (es) * 2005-10-21 2010-06-04 Glaxo Group Limited Compuestos triciclos peri-condensados utiles como agentes antibacterianos.
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
ATE465163T1 (de) 2005-12-22 2010-05-15 Glaxo Group Ltd Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
GB0601951D0 (en) * 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
PT2593452T (pt) 2010-07-14 2017-04-24 Novartis Ag Compostos heterocíclicos agonistas do receptor ip
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP5907005B2 (ja) * 2012-09-04 2016-04-20 エヌ・イーケムキャット株式会社 ビフェニル化合物の合成方法
JP5907006B2 (ja) * 2012-09-04 2016-04-20 エヌ・イーケムキャット株式会社 ビフェニル化合物の合成方法
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US9741941B2 (en) 2014-04-29 2017-08-22 Universal Display Corporation Organic electroluminescent materials and devices
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138572A (en) * 1978-04-17 1979-10-27 Kyowa Hakko Kogyo Co Ltd Novel isoquinoline derivative
JPS57203068A (en) * 1981-06-08 1982-12-13 Teikoku Hormone Mfg Co Ltd Novel 1-phenylisoquinoline derivative
FR2567520B1 (fr) * 1984-07-11 1987-01-02 Carpibem Nouvelles phenyl-naphthyridines, leur procede de preparation, medicaments les contenant, notamment anti-ulceres
JPS6230780A (ja) * 1985-04-17 1987-02-09 Ss Pharmaceut Co Ltd １，７−ナフチリジン誘導体及びこれを含有する薬剤
JPS6348277A (ja) * 1986-08-19 1988-02-29 Ss Pharmaceut Co Ltd ８−ピペラジニル−１，７−ナフチリジン誘導体
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US4956371A (en) * 1989-09-19 1990-09-11 Euroceltique, S.A. Substituted isoquinolines and methods of using same
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
AU6279598A (en) * 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists

Also Published As

Publication number Publication date
DE69720493D1 (de) 2003-05-08
PL189280B1 (pl) 2005-07-29
TR199900920T2 (xx) 1999-06-21
EP0934320A1 (en) 1999-08-11
JP2001502717A (ja) 2001-02-27
CN1234800A (zh) 1999-11-10
DK0934320T3 (da) 2003-07-14
ATE236155T1 (de) 2003-04-15
IL129502A0 (en) 2000-02-29
WO1998018796A1 (en) 1998-05-07
AU6908498A (en) 1998-05-22
PE10899A1 (es) 1999-03-03
ID18623A (id) 1998-04-30
US6136821A (en) 2000-10-24
DE69720493T2 (de) 2003-12-24
JP4451496B2 (ja) 2010-04-14
HK1022305A1 (en) 2000-08-04
CZ146699A3 (cs) 1999-08-11
NO991903D0 (no) 1999-04-21
ES2196377T3 (es) 2003-12-16
BR9713280A (pt) 1999-11-03
HUP9904204A2 (hu) 2000-05-28
SI0934320T1 (en) 2003-08-31
SK283562B6 (sk) 2003-09-11
TW399052B (en) 2000-07-21
SK55799A3 (en) 1999-10-08
MY132642A (en) 2007-10-31
EP0934320B1 (en) 2003-04-02
PT934320E (pt) 2003-07-31
NO312677B1 (no) 2002-06-17
KR20000052832A (ko) 2000-08-25
NZ335363A (en) 2000-11-24
HUP9904204A3 (en) 2000-06-28
GB9622386D0 (en) 1997-01-08
CN1103773C (zh) 2003-03-26
BR9713280B1 (pt) 2010-12-14
KR100524329B1 (ko) 2005-11-01
CO4910164A1 (es) 2000-04-24
PL332738A1 (en) 1999-10-11
CA2269946A1 (en) 1998-05-07
ZA979593B (en) 1998-04-28
AU724471B2 (en) 2000-09-21
NO991903L (no) 1999-04-21
CA2269946C (en) 2007-01-23
IL129502A (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AR009128A1 (es) Un compuesto de 8-aril-1,7-naftiridina, composiciones farmaceuticas que lo comprenden, utilizacion de dicho compuesto para la fabricacion de medicamentos,procedimiento para la preparacion de tal compuesto y productos intermedios utilizados en dicha preparacion
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
EE200200045A (et) Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
FI831009L (fi) Spiro/4(3+n)/-2-aza-3-karboxylsyra-derivat, foerfarande foer deras framstaellning, dessa innehaollaaemnen och deras anvaendning
ES2115237T3 (es) Fenil heterociclos como inhibidores de la ciclooxigenasa-2.
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
DK0863891T3 (da) (Methylsulfonyl)phenyl-2-(5H)-furanoner som COX2-inhibitorer
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
BR0114881A (pt) Derivados de benzoxazinona, sua preparação e uso
DE69008791D1 (de) Benzopyranverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen.
EE04496B1 (et) Tetrahüdro-gamma-karboliinid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad kompositsioonid
AR027335A1 (es) Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen
AR028947A1 (es) Compuestos novedosos
AR018032A1 (es) Derivados del indol-aril sustituidos, un procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de dichos compuestos parala fabricacion de un medicamento
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
AR016594A1 (es) DERIVADOS DE 3,4,5,7-TETRAHIDRO-PIRROLO[3',4':4,5]TIENO[2,3-d]PIRIMIDINA 3-SUSTITUIDOS Y SU USO PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS
ATE39692T1 (de) Phenylalkansaeure-derivate.
ES8104812A1 (es) Un procedimiento para la preparacion de derivados de aceto- fenona substituidos
JPS6470412A (en) Medicinal composition
BR9609991A (pt) Carbamoilcarboxamida composição adequada para controlar fungos nocivos processos para a preparação de uma carbamoilcarboxamida para preparação da composição e para controle de fungos nocivos e uso de um composto ou de uma composição
DK477783A (da) 1,3,4,6,7-11b-hexahydro-7-aryl-2h-pyrazino(2,1-a)-isoquinoliner, fremgangsmaade til fremstilling heraf og deres anvendelse som mellemprodukter og laegemidler

Legal Events

Date Code Title Description
FB Suspension of granting procedure